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In malarial endemic countries especially in the tropics, conventional antimalarial drugs are used with herbal remedies 
either concurrently or successively.  Khaya grandifoliola is one of such popular herbs used in the treatment of malaria. 
Various doses of ethanol extract of K. grandifoliola stem bark (50-400 mg/kg/day) were administered orally to Swiss albino mice 
infected with Plasmodium yoelii nigerense. A dose of 100 mg/kg/day of the extract was also combined with 2.5 mg/kg/day of 
chloroquine or 6.25 mg/kg/day of halofantrine in both early and established malaria infection test models. The results showed 
that in the early malaria infection test, K. grandifoliola in combination with chloroquine or halofantrine elicited enhanced anti-
plasmodial effect in the established infection, there was significantly greater parasite clearance following administration of the 
combination when compared to the effects of K. grandifoliola or the conventional drugs alone. The mean survival period of 
parasitized animals was also enhanced by the extract/halofantrine combination. Lower therapeutic doses of halofantrine may be 
required to potentiate parasite clearance when used in combination with K. grandifoliola. This may constitute great advantage to 
halofantrine which is associated with cardiotoxicity at high doses. 
 





 Antimalarial drug resistance is one of the greatest challenges of malaria therapy.  Resistance accounts for 
recrudescence and severity of infections in some parts of the world (Peters, 1982).  Many commonly used antimalarial drugs are 
chemically related such that development of resistance to one drug can result in resistance to others. For example, cross-
resistance between the 4-aminoquinolines, chloroquine and amodiaquine, has been reported (Bloland, 2001) as a result of 
ineffectiveness of commonly used antimalarial drugs, the use of alternative medicine either exclusively or along with 
conventional medicines has becomes common feature. This situation is prevalent in developing tropical countries where modern 
medicines are not affordable to a majority of the rural populations (Kremsner and Kritna, 2004). Up to 80% of African population 
use traditional medicine especially plant remedies in the management of diseases including malaria (WHO, 2002). Often, 
antimalarial herbal therapies are used concurrently, prior or after the use of conventional antimalarial drugs in West Africa. Very 
few reports are available on the interaction of herbal anti-malarial products with synthetic drugs. One of such reports indicates 
that some local African populations use herbal products in combination with chloroquine for enhancement of activity 
(Rasoanaivo et al. 1998). 
  Either of pharmacodynamic or pharmacokinetic interactions can result in synergism, additivity or antagonism. It is 
therefore most desirable to evaluate the interaction between common herbs used in the management of malaria and some of the 
conventional antimalarial drugs.  More so, the use of combination of two or more drugs as a way of delaying or overcoming 
development of drug resistance is topical in malarial chemotherapy research (WHO, 2000). Combination of Artemisinin 
derivatives with other antimalarial drugs has become a standard practice in malaria chemotherapy. Antimalarial combination 
chemotherapy is widely advocated because combination therapies can increase efficacy, shorten duration of treatment hence 
improve compliance in addition to reduction in the risk of resistant parasites arising through mutation during therapy (WHO, 
2001). 
Aqueous decoction of K. grandifoliola (Benin Mahogany or timber) is commonly used by traditional medical 
practitioners in West Africa in the management of malaria.  This plant has been scientifically evaluated for its anti-malarial 
activity (Makinde et al 1989; Agbedahunsi et al, 1998), anti-inflammatory and toxic effects (Agbedahunsi et al, 2004), effects on 
red blood cells and bone mineral content in rats (Bumah et al, 2005a) and on some biochemical parameters in rats (Bumah et al, 
2005b).   A bicyclo (3, 3, 1) nonane derivative of phragmaline named grandifolioline, has been isolated from the anti-malarial 
fraction of this plant by Agbedahunsi et al. (1998). 




The   present study evaluates the in vivo antimalarial activities of aqueous extract of the plant alone and in combination 
with two commonly available anti-malarial drugs (chloroquine and halofantrine) against rodent malaria parasite in mice  
 
 
Materials and Methods 
Animals and Parasite 
 
Swiss Albino mice (male and female) of weight range of 18 to 22 g were used for this study. The animals were 
obtained from Central Animal House, University of Ibadan, Ibadan, Oyo State, Nigeria and were kept in well ventilated animal 
house in the Faculty of Pharmacy Obafemi Awolowo University Ile-Ife. The animals were allowed to acclimatize for 7 days prior 
to the commencement of the experiment, kept at normal room temperature in a group of five per cage. They all received animal 
chow and water ad libitum throughout the duration of the experiment. The “Principle of Laboratory Animal Care” (NIH 
publication No 85-23) guidelines and procedures were followed in the study (NIH publication. 1985). 
Rodent Plasmodium yoelii nigerense (chloroquine resistant strain) obtained from the National Institute of Medical Research, 
Lagos, Nigeria, was used to inoculate the animals. 
 
Collection, Preparation and Extraction of the stem bark of K. grandifoliola 
 
The stem bark of K. grandifoliola was collected at Igasi village near Ikare Akoko, Ondo State, Nigeria in January 2005 
by Mr A. Akanle. Specimen of the stem bark was authenticated by Dr. C. Illoh of Botany Department, Obafemi Awolowo 
University, Ile Ife, Nigeria.  A herbarium specimen with voucher specimen number IFE 15320 was deposited at the University 
herbarium located in the Botany department. The barks were chopped, dried in an oven for 48 hours at 60 oC and then powdered 
using a grinding machine (Christy Norris, UK). The powder was kept in a well closed, amber-coloured bottle until when needed. 
K. grandifoliola stem bark powder (600 g) was extracted with 50% aqueous ethanol in a Soxhlet extractor for 72 hr. 
The resulting extract was concentrated in vacuo to reduce the volume and finally freeze dried using an Edward Pirani 10 
lyophylizer, UK. The dried powder extract was then stored in well sealed amber bottle for further analyses. 
 
In vivo antimalarial studies using the early malarial infection model 
Assessment of Antimalarial actions of K. grandifoliola, chloroquine and halofantrine 
 
The early malarial infection test according to Peters et al (1975) as modified by Makinde et al (1989) was used. Sixty 
five Swiss Albino mice were divided into 13 sub groups (n=5).  
Group A consisted of four sub-groups. Each sub-group separately received different doses of K. grandifoliola stem bark extract at 
the doses of 50, 100, 200 and 400 mg/kg body weight/day 
Group B consisted of four such groups. Each sub group received different doses of halofantrine at  6.25, 12.5, 25.0 and 50.0  
mg/kg /day. 
Group C also consisted of four sub groups. Each sub group received separately different doses of chloroquine at 1.25, 2.5,5 and 
10  mg/kg/day 
Group D consisted of a single group of five mice. This served as the control group. The mice in this group received 0.2 ml 
distilled water. 
All the mice tested received standard inoculums of 1 x 107 chloroquine resistant Plasmodium yoelii nigerense infected 
erythrocytes by intraperitoneal (I.P) route at the commencement of the experiment. Single oral doses of the test drugs or extract 
were administered to the animals 3 hr after each inoculum’s for four consecutive days. On the fifth day, tip of each mouse was 
cut with sharp dissecting scissors to withdraw drops of blood from the animal’s tail onto scratch free slides, stained with Giemsa 
stain and examined microscopically. The level of parasitaemia (%) was evaluated from the equation: 
Total number of PRBC   X        100 
  Total number of RBC 
 
Where PRBC: Parasitized red blood cells; RBC: Red blood cells. 
 
Assessment of antimalarial effects of K. grandifoliola stem bark extract in combination with chloroquine or halofantrine 
  
Thirty mice were divided into six groups (n=5). The experiment was carried out as described above.  
Mice in Group E received 100 mg/kg body weight/day of the ethanol extract;  
Group F received 2.5 mg/kg body weight/day of chloroquine.  
Group G received 6.25 mg/kg body weight/day of halofantrine.  
Group H received the extract/ chloroquine mixture in combination dose of 100 :2.5 mg/kg /day (  
Group I received the extract/halofantrine mixture in combination dose of 100: 6.25 mg/kg/day  
Group J served as the control. The mice received 0.2 ml of water orally as in the other groups. 
Thin films of blood from the mice were prepared on the fifth day after inoculation with the P. yoelii  nigerense and the 
percentage parasitaemia determined as described above. 
 






Assessment of interaction of K. grandifoliola stems bark extract in combination with low doses of chloroquine and 
halofantrine   
 
Thirty mice were divided into six groups (K to P, n=5) and the experiment was executed as described above but with 
lower doses of chloroquine and halofantrine in the combination treatments.  
Group K mice received 100 mg/kg/day dose of the extract alone 
Group L mice received 1.25 mg/kg day of chloroquine alone 
Group M mice received 3.13 mg/kg /day of halofantrine alone.  
Group N mice received extract/ chloroquine mixture in combination dose of 100:1.25 mg/kg /day  
 Mice in group O received extract/halofantrine mixture in combination dose of 100:3.125 mg/kg /day  
Mice in group P served as the control, they received 0.2 ml water.  
Assessment of percentage parasitaemia was as described above. 
 
In vivo antimalarial experiments using the established malarial infection model 
Assessment of interaction between K. grandifoliola stem bark extract and chloroquine or halofantrine 
 
A modified Ryley and Peters (1970) method was used. Thirty mice were divided into six groups (Q-V, n=5). Each 
mouse was inoculated with 1x107 Plasmodium yoelii  nigerense infected erythrocytes on the first day of the experiment (Day 1). 
The mice were not treated until the parasitaemia was developed and established. On day 4, (72 hr after inoculation), the mice 
were treated orally with the extract and the drug, singly and in combinations.  
Group Q mice received 100 mg/kg /day) of the extract. 
 Group R mice, received 2.5 mg/kg /day of chloroquine,  
Group S mice received, 6.25 mg/kg /day of halofantrine,  
Group T mice received a combination of the extract and chloroquine at the doses of 100:2.50 mg/kg/day,  Group U mice received 
a combination of the extract and halofantrine at the doses of 100:6.25 mg/kg /day, extract: halofantrine)  
Group V served as the control the mice ad received 0.2 ml water orally.  
All the animals were treated daily for five days and were assessed daily for the 
five days of treatment. On each day of the assessment, percentage parasitaemia and percentage parasite clearance for each of the 
mice relative to the control was determined. 
The percentage suppression of parasitaemia and parasite clearance for the plant extract and/or drug treatments were calculated as 
follows: 
[(Mean % parasitaemia in the negative control group – Mean % parasitaemia in the tested group) / Mean % parasitaemia in the 
negative control group] x 100 
After the five days of drug and/or extract administration, the mice were observed till day 28. Any death that occurred 
during this period was noted and the mean survival time was determined. 
 
Data and Statistical analysis 
 
The data were as analyzed using Statistical package for Social Scientists (SPSS) version 12 computer software. Level 
of significant differences between the groups receiving different treatments was determined using one-way ANOVA followed by 





Effects of various doses of the extract of K. gradifoliola, chloroquine and halofantrine on P. yeolii nigerense when 
administered separately in the early malarial infection tests are presented in Tables 1, 2 and 3, respectively. The percentage 
chemosuppression was dose-dependent. The highest dosages of the extract and the conventional drugs gave about 70 percent 
chemosuppression. K. grandifoliola at 400 mg/ kg /day gave 79.9%, while chloroquine at 10 mg/kg body weight / day and 
halofantrine at 50 mg/kg body weight/day resulted in 78.8 % and 69.1% chemosuppression, respectively. Based on these results, 
the sub optimal doses were obtained for the extract and the conventional drugs. Dose of K. gradiofoliola extract (100 mg/ kg 
/day) gave 22.3 % suppression of parasitaemia. The sub-optimal dose for chloroquine was found to be 2.5 mg/kg body 
weight/day (41.9%) while halofantrine at 6.25mg/kg/body weight/day had 29.1 % (Tables 1-3) 
These sub-optimal doses were used to assess the interaction of K. grandifoliola stem bark with the conventional antimalarial 
drugs in subsequent combination treatments. 
Table 4 shows the results of the combination treatments of K. grandifoliola stem bark extract with conventional drugs 
at sub-optimal doses using the early malarial infection test model. Extract/ chloroquine combination resulted in 55.2% 
suppression, while extract/halofantrine combination gave 66% suppression. 
The results of the combination studies at low dosages of the conventional drugs are presented in Table 5.  Half the sub-optimal 
doses of chloroquine (1.25 mg/kg /day) and halofantrine (3.13 mg/kg /day) were used in combination with the sub-optimal dose 




of K. grandifoliola ethanol extract (100 mg/ kg /day). The suppression for the extract/chloroquine combination was 29.6% and 
36.4% for the extract/halofantrine combination. 
The interaction of the ethanol extract with Chloroquine and halofantrine drugs were assessed for parasite clearance when the 
parasites were already established in the mice at sub-optimal dose levels and the results was presented in Table 6. There were 
significant increases in percentage clearance for the extract/chloroquine and extract/halofantrine compared to the effects of the 
drugs or extract given separately. 
 As part of the established infection test, the mean survival period of the parasitized mice treated with the drugs singly or in 




Table 1: Antimalarial activities of extract of K. grandifoliola stem bark at different doses in an early malarial infection in mice (4 
days test) 
 





Water (control) 0.0d 
Mean with different alphabets are significantly different from each other (p<0.05) 
 
 
Table 2: Antimalarial activity chloroquine at different doses in an early malarial infection in mice (4 days test) 
 





Water (control) 0.0e 
Mean with different alphabets are significantly different from each other (p<0.05) 
 
 
Table 3: Antimalarial activity halofantrine at different doses in an early malarial infection in mice (4 days test) 
 
 





Water (control) 0.0d 
Mean with different alphabets are significantly different from each other (p<0.05) 
 
 
Table 4: Results of interaction of K. grandifoliola stem bark extract in combination with chloroquine or halofantrine at sub-
optimal doses in early malarial infection test. 
 
Dose of drugs (mg/kg/day) Mean % Suppression of Parasitaemia 
Extract (100) 22.3a 
Chloroquine (2.5) 37.4c 
Halofantrine (6.25) 28.4b 
Extract and Chloroquine (100:2.5) 55.2d 
Extract and Halofantrine (100:6.25) 66.0e 
Water (control) 0.0f 









Table 5: Results of interaction of K. grandifoliola stem bark extract in combination with lower  doses of chloroquine or 
halofantrine in early malarial infection test 
 
Dose of drugs (mg/kg/day) Mean % Suppression of Parasitaemia 
Extract (100) 26.8c 
Chloroquine (1.25) 9.1a 
Halofantrine (3.125) 13.2b 
Extract and Chloroquine (100:1.25) 29.6d 
Extract and Halofantrine (100:3.125) 36.4e 
Water (control) 0.0f 
Mean with different alphabets are significantly different from each other (p<0.05) 
 
 
Table 6: Results on the assessment of interaction between K. grandifoliola stem bark extract and chloroquine or halofantrine in 
established malaria infection in mice. 
 
Dose of drugs (mg/kg/day) Mean % of Parasite clearance 
Extract (100) 27.3a 
Chloroquine (2.5) 39.7c 
Halofantrine (6.25) 33.1b 
Extract and Chloroquine (100:2.5) 61.7d 
Extract and Halofantrine (100:6.25) 69.7e 
Water (control) 0.0f 
Mean with different alphabets are significantly different from each other (p<0.05) 
 
 
Table 7: Mean survival period following combination of K. grandifoliola stem bark extract and chloroquine or halofantrine in 
established malaria infection in mice. 
 
  
Dose of drugs (mg/kg/day) Mean Survival (in days) 
Extract (100) 14.2a 
Chloroquine (2.5) 18.0a 
Halofantrine (6.25) 25.1b 
Extract and Chloroquine (100:2.5) 16.4a 
Extract and Halofantrine (100:6.25) 28.0b 
Water (control) 10.4c 





The stem bark of K. grandifoliola is widely used as decoction by traditional healers in Nigeria however some 
traditional healers soak the stem bark along with some other herbs with dilute ethanol to manage febrile conditions. As such 50 
percent ethanol / water (v/v) was used as extraction solvent. Beside, ethanol being an organic solvent should possess better 
extractive capability than water (inorganic polar solvent) to extract the putative organic material. The adult human therapeutic 
dose for chloroquine and halofantrine in the management of malaria are 10 mg/kg and 50 mg/kg respectively. Based on this fact 
two fold serial dilution of 10mg/ kg i.e. (5, 2.5 and 1.25) mg/kg  was prepared and used for chloroquine while 25, 12.5 and 6.25 
mg/kg doses were used for halofantrine respectively. Based on these concentrations sub-optimal doses were determined for the 
two drugs. Sub- optimal doses were chosen as doses that produced less than 50% suppression or parasite clearance in the early 
malarial infection or established malarial infection respectively.      
The spread of malaria parasite resistance to commonly available antimalarial drugs  especially the monotherapeutic 
drugs such as chloroquine, amodiaquine, halofantrine etc is posing increasing problems for the provision of suitable treatment of 
malaria. This has resulted in high level of malaria treatment failure which serves as one of the basis for the replacement of first-
line treatment. Resistance has emerged to all classes of antimalarial drugs including artemisinine and its derivatives (WHO, 
2003a). Combination therapy (CT) which enhances efficacy and reduces the emergence of resistant parasite strains is now 
recommended (WHO, 2003a; White 2004; WHO, 2006). This entails the simultaneous use of two or more blood schizontocidal 
drugs with independent modes of action and different biochemical targets in the parasite (WHO, 2006). CT can be fixed therapy 
in which the components of the drugs are co-formulated or multi-drug therapy in which the components are co-administered 
separately. CT could lengthen the effective life span of chemotherapeutic agents by reducing the chances of emergence of 
resistant mutants (WHO, 2003a). Chemotherapeutic interaction studies involving the combination therapy have been used to 
evaluate compounds in the management of malaria (Price et al, 1996; Attaran et al, 2004). 





A dose-dependent suppression of parasitaemia was observed in the extract and the standard drugs tested (Tables 1-3). 
However, increase in halofantrine dosage up to 50 mg/kg/day resulted in marginal activity which implied that absorption of 
halofantrine has a maximum limit dose (25 mg/kg/day) in this experiment (Table 3). This result confirmed the findings of 
Karbwang and Na Bangchang, 1994 wherein it was reported that due to halofantrine poor aqueous solubility, its absorption after 
oral administration even after increasing drug doses was limited. 
The effect of combination of the extract with halofantrine at sub-optimal dose levels in both early malaria infection and 
the established infection models showed that the effect of the combination was higher than the sum of the effects of the extract 
and halofantrine acting separately (Tables 4 and 6). Thus, parasite suppression and clearance for K. grandifoliola/halofantrine 
combination (100:6.25 mg/kg body weight/day) were significantly higher (p<0.05) when compared to the sum of the effect of the 
extract and halofantrine separately. These observations tend to suggest a synergistic interaction between the extract and 
halofantrine. On the other hand, the effects of combination of the extract with chloroquine in both infection models were 
indicative of additive interaction since the effects of the combination were comparable to sum of the separate effects of the 
extract and chloroquine. 
At very low doses of the conventional drugs (chloroquine 1.25, and halofantrine, 3.13 mg/kg body weight/ day), the 
suppression of parasitaemia was equally very low. Additive effect was still observed at these low doses in the extract/halofantrine 
combination. The increase in percentage suppression in the extract/chloroquine combination was just marginal. In spite of these 
low values, the differences were still significant (p< 0.05) which is an evidence of the effect of the interaction (Table 5). Results 
of mean survival period do not parallel those of parasite clearance. For example, the mean survival period of the 
extract/chloroquine combination was not significantly different from the survival period of animals treated with chloroquine or 
extract alone (Table 7) inspite of the significant increase (p<0.05)  in the parasite clearance due to the combination (Table 6). In a 
study by Nwafor et al. (2003), it was reported that concomitant administration of chloroquine sulphate and aqueous extract of 
Azadirachta indica impaired the bioavailability of chloroquine resulting in antagonist effect between chloroquine and the plant 
extract. A .indica and K. grandifoliola belong to the Meliaceae family and contain similar constituents limonoids. The decrease in 
the mean survival period of the extract/chloroquine combination could be due to this bioavailability theory or otherwise. 
Therefore, further studies are required to verify the toxicological implications of combinations of K. grandifoliola with 
chloroquine or halofantrine  
In this study, it was observed that chemosuppresion or parasite clearance in the early or established infection tests 
respectively was below 80%. This is due to the resistant strain of the parasite used for the study. In spite of this observation the K. 




In response to wide spread multidrug resistance of malaria parasites to monotherapies, this study shows that K. 
grandifoliola bark extract in combination with halofantrine is associated with enhanced efficacy.  The combination with 
halofantrine resulted in 100 % survival of the infected animals throughout the 28 days of study in the established antimalarial 
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